FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) for treating certain adults with limited-stage small cell lung cancer (SCLC). The...
